{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:57:28Z","timestamp":1785895048316,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The INPULSIS, SENSCIS and INBUILD trials were funded by Boehringer Ingelheim International GmbH (BI). BI is funding the Rapid Service Fees for this manuscript."},{"name":"Ruhrlandklinik, Westdeutsches Lungenzentrum am Universit\u00e4tsklinikum Essen gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02145-x","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:03:13Z","timestamp":1652688193000},"page":"3392-3402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9767","authenticated-orcid":false,"given":"Francesco","family":"Bonella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus B.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"2145_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958\u201368.","journal-title":"N Engl J Med"},{"key":"2145_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/resp.12931","volume":"22","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Bendstrup E, Wells AU, Hilberg O. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22:494\u2013500.","journal-title":"Respirology"},{"key":"2145_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.39971","volume":"69","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69:542\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"2145_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/crj.12700","volume":"12","author":"M Doubkov\u00e1","year":"2018","unstructured":"Doubkov\u00e1 M, \u0160vancara J, Svoboda M, et al. EMPIRE Registry, Czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12:1526\u201335.","journal-title":"Clin Respir J"},{"key":"2145_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200:1258\u201366.","journal-title":"Am J Respir Crit Care Med"},{"key":"2145_CR6","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","volume":"57","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57:2002718.","journal-title":"Eur Respir J"},{"key":"2145_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145:723\u20138.","journal-title":"Chest"},{"key":"2145_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1183\/13993003.01565-2015","volume":"47","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47:1767\u201375.","journal-title":"Eur Respir J"},{"key":"2145_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/jcm9082499","volume":"9","author":"E Krauss","year":"2020","unstructured":"Krauss E, El-Guelai M, Pons-Kuehnemann J, et al. Clinical and functional characteristics of patients with unclassifiable interstitial lung disease (uILD): long-term follow-up data from European IPF Registry (eurIPFreg). J Clin Med. 2020;9:2499.","journal-title":"J Clin Med"},{"key":"2145_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80:219\u201327.","journal-title":"Ann Rheum Dis"},{"key":"2145_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/13993003.00357-2015","volume":"47","author":"JJ Solomon","year":"2016","unstructured":"Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588\u201396.","journal-title":"Eur Respir J"},{"key":"2145_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/thoraxjnl-2017-210035","volume":"73","author":"A Gimenez","year":"2018","unstructured":"Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018;73:391\u20132.","journal-title":"Thorax"},{"key":"2145_CR13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69:1670\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"2145_CR14","doi-asserted-by":"publisher","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","volume":"55","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55:2000085.","journal-title":"Eur Respir J"},{"key":"2145_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.113.208223","volume":"349","author":"L Wollin","year":"2014","unstructured":"Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"2145_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434\u201345.","journal-title":"Eur Respir J"},{"key":"2145_CR17","doi-asserted-by":"publisher","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","volume":"54","author":"L Wollin","year":"2019","unstructured":"Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.","journal-title":"Eur Respir J"},{"key":"2145_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079\u201387.","journal-title":"N Engl J Med"},{"key":"2145_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"2145_CR20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","volume":"7","author":"TM Maher","year":"2019","unstructured":"Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7:771\u20139.","journal-title":"Lancet Respir Med"},{"key":"2145_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1874306402014010022","volume":"14","author":"L Lancaster","year":"2020","unstructured":"Lancaster L, Goldin J, Trampisch M, et al. Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis. Open Respir Med J. 2020;14:22\u201331.","journal-title":"Open Respir Med J"},{"key":"2145_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"2145_CR23","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","volume":"59","author":"KR Flaherty","year":"2021","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2021;59:2004538.","journal-title":"Eur Respir J"},{"key":"2145_CR24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"key":"2145_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","volume":"42","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42:750\u20137.","journal-title":"Eur Respir J"},{"key":"2145_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","volume":"19","author":"C Chan","year":"2019","unstructured":"Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med. 2019;19:192.","journal-title":"BMC Pulm Med"},{"key":"2145_CR27","doi-asserted-by":"publisher","first-page":"2004507","DOI":"10.1183\/13993003.04507-2020","volume":"58","author":"M Selman","year":"2021","unstructured":"Selman M, Pardo A. When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases. Eur Respir J. 2021;58:2004507.","journal-title":"Eur Respir J"},{"key":"2145_CR28","doi-asserted-by":"publisher","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","volume":"51","author":"AU Wells","year":"2018","unstructured":"Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692.","journal-title":"Eur Respir J"},{"key":"2145_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360.","journal-title":"Lancet Respir Med"},{"key":"2145_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/art.42075","author":"E Matteson","year":"2022","unstructured":"Matteson E, Kelly C, Distler JHW, et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol. 2022. https:\/\/doi.org\/10.1002\/art.42075.","journal-title":"Arthritis Rheumatol"},{"key":"2145_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","volume":"20","author":"M Ackermann","year":"2017","unstructured":"Ackermann M, Kim YO, Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis. 2017;20:359\u201372.","journal-title":"Angiogenesis"},{"key":"2145_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","volume":"193","author":"U Costabel","year":"2016","unstructured":"Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193:178\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"2145_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","volume":"72","author":"M Kolb","year":"2017","unstructured":"Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340\u20136.","journal-title":"Thorax"},{"key":"2145_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.rmed.2018.11.012","volume":"146","author":"KK Brown","year":"2019","unstructured":"Brown KK, Flaherty KR, Cottin V, et al. Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019;146:42\u20138.","journal-title":"Respir Med"},{"key":"2145_CR35","doi-asserted-by":"publisher","first-page":"00127","DOI":"10.1183\/23120541.00127-2018","volume":"5","author":"CJ Ryerson","year":"2019","unstructured":"Ryerson CJ, Kolb M, Richeldi L, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. 2019;5:00127\u20132018.","journal-title":"ERJ Open Res"},{"key":"2145_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","volume":"20","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20:3.","journal-title":"BMC Pulm Med"},{"key":"2145_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12931-021-01695-y","volume":"22","author":"I Glaspole","year":"2021","unstructured":"Glaspole I, Bonella F, Bargagli E, et al. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021;22:125.","journal-title":"Respir Res"},{"key":"2145_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8:925\u201334.","journal-title":"Lancet Respir Med"},{"key":"2145_CR39","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2:E71\u201383.","journal-title":"Lancet Rheumatol"},{"key":"2145_CR40","doi-asserted-by":"publisher","first-page":"175346662110397","DOI":"10.1177\/17534666211039771","volume":"15","author":"AM Nambiar","year":"2021","unstructured":"Nambiar AM, Walker CM, Sparks JA. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Ther Adv Respir Dis. 2021;15:17534666211039772.","journal-title":"Ther Adv Respir Dis"},{"key":"2145_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","volume":"22","author":"V Cottin","year":"2021","unstructured":"Cottin V, Richeldi L, Rosas I, et al. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021;22:84.","journal-title":"Respir Res"},{"key":"2145_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9:96\u2013106.","journal-title":"Lancet Respir Med"},{"key":"2145_CR43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"2145_CR44","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02145-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T22:12:58Z","timestamp":1656454378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02145-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}